As NL­RP3 play­ers head for first clin­i­cal face-off, No­vo, Sanofi fu­el trans-At­lantic con­tender with $55M

In the rel­a­tive short his­to­ry of in­flam­ma­some re­search, Adam Keeney sees two time points mark­ing ma­jor break­throughs: the ear­ly 2000s, when the role of in­flam­ma­somes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER